Royalty Analysis in the Biotechnology Industry
This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
Background
Intensity determined the extent to which certain patents in the field of molecular diagnostics were unenforceable due to prosecution laches. Intensity also performed an analysis of damages relating to alleged infringement of patented technology by quantifying reasonable royalties.
Our Analysis
Intensity was retained to analyze the ongoing investments, marketing, and research in a biotechnology company specializing in molecular diagnostics. Intensity assessed the extent to which these were or were not sunk costs and the extent to which these costs precluded alternative research and investment spending. Intensity then determined a reasonable and market-based royalty for technology as part of molecular diagnostics testing kits, based on consideration of the market for these kits, the licensing policies and histories of both companies, product sales and profitability.
Intensity also performed an analysis of damages relating to alleged infringement of patented technology by quantifying reasonable royalties based on consideration of relevant licensing agreements, accused sales and profitability, and the unique contribution of the patented technology.
Economic issues include apportionment, licensing, and reasonable royalties.
Latest Insights
News | November 10, 2025
New York and California Step Forward as Federal Enforcement Retreats
As federal regulatory priorities narrow under the Trump administration, state attorneys general and financial regulators are preparing to take on a more active role in white collar and securities enforcement. With the DOJ and the SEC recalibrating their focus, states such as New York and California are asserting their authority to fill gaps in corporate oversight.
Article | November 7, 2025
Policy News and Stock Market Volatility
When it comes to explaining stock market volatility, the story is rarely straightforward. In their article Policy News and Stock Market Volatility for the Journal of Financial Economics, Director Kyle Kost and coauthors Scott R. Baker, Nicholas Bloom, and Steven J. Davis revisit Robert Shiller’s 1981 finding that stock market fluctuations cannot be fully explained by realized future dividends.
See All Insights
Talk to Our Insightful Experts